The Chicago Entrepreneur

FDA approves GSK’s RSV vaccine for high-risk adults ages 50 to 59, expanding shot’s reach

The FDA’s expanded approval could help GSK maintain its dominance in the RSV market, which includes shots from Pfizer and Moderna.

Previous post Beyoncé tickets and a luxury trip to Bali: What Supreme Court justices got as gifts
Next post Nadella, Narayen among tech CEOs investing in cricket’s American dream